Abstract
Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.
| Original language | English |
|---|---|
| Pages (from-to) | 877-885 |
| Number of pages | 9 |
| Journal | European Journal of Endocrinology |
| Volume | 161 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2009 |
Keywords
- diabetes
- insulin secretion
- nateglinide
- postprandial hyperglycaemia